Hemab Therapeutics (NASDAQ:COAG) Hits New 1-Year High – Here’s What Happened

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $51.00 and last traded at $51.00, with a volume of 4884 shares. The stock had previously closed at $49.29.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on COAG. HC Wainwright increased their price target on Hemab Therapeutics from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective for the company. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Evercore began coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $55.00 price target (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

Hemab Therapeutics Price Performance

The firm’s 50 day moving average is $31.15. The firm has a market cap of $2.25 billion and a PE ratio of -2.01.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the acquisition, the insider owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have bought a total of 2,970,541 shares of company stock valued at $55,459,603 in the last ninety days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.